Sodium Lauryl Sulfate

Summary

Sodium Lauryl Sulfate (CHEMBL23393) is an approved small-molecule detergent; indicated across 7 conditions including allergic disease and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 9
• Chemistry: 288.38 Da · C12H25NaO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL23393
Name	Sodium Lauryl Sulfate
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	3423265
ChEBI	CHEBI:8984
Molecular formula	C12H25NaO4S
Molecular weight	288.38
InChIKey	DBMJMQXJHONAFJ-UHFFFAOYSA-M

SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]

IUPAC name: sodium dodecyl sulfate

ChEBI definition: An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.

Other ChEBI roles (chemical / environmental): detergent.

Also known as: E487, NSC-402488, Sodium dodecyl sulfate, Sodium laurilsulfate, Sodium lauryl sulfate, synthetic, Texapon k 12 p, sodium dodecyl sulfate, sodium dodecylsulphate, Sodiumdodecylsulfate, SID17388729, SID17388731

Patent coverage: 353,250 distinct patent families (864,340 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: ATP-dependent DNA helicase Q1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thyrotropin receptor, Bifunctional epoxide hydrolase 2, Alpha-galactosidase A, Cruzipain, Mitogen-activated protein kinase 1, Lethal factor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15917	7	Potency	100	nM	CHEMBL_ACT_4671073
EPHX2	5.26	IC50	5500	nM	CHEMBL_ACT_19307232

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
allergic disease	3	MONDO:0005271	MONDO:0005271
skin disorder	1	MONDO:0005093	EFO:0000701
tinea pedis	1	MONDO:0005984	EFO:0007512
disease of the tendon	1	MONDO:0100010	EFO:1001434
lice infestation	1	MONDO:0003472	MONDO:0003472

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	8
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00680095	PHASE1	COMPLETED	Cumulative Irritation Test
NCT00781664	PHASE1	COMPLETED	Cumulative Irritation Test
NCT01430312	PHASE1	COMPLETED	21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
NCT02061813	PHASE1	COMPLETED	Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
NCT02117752	PHASE1	COMPLETED	Dermal Tolerability of Dapsone Gel in Healthy Volunteers
NCT02227069	PHASE1	COMPLETED	Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers
NCT02256930	PHASE1	COMPLETED	Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers
NCT03502434	PHASE1	COMPLETED	A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers
NCT01501409	Not specified	COMPLETED	Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).